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The present study evaluated mitochondrial respiratory chain and creatine kinase activities after administration of harmine (5,
10, and 15mg/kg) and imipramine (10, 20, and 30mg/kg) in rat brain. After acute treatment occurred an increase of creatine
kinase in the prefrontal with imipramine (20 and 30mg/kg) and harmine in all doses, in the striatum with imipramine (20 and
30mg/kg) and harmine (5 and 10mg/kg); harmine (15mg/kg) decreased creatine kinase. In the chronic treatment occurred an
increase of creatine kinase with imipramine (20mg/kg), harmine (5mg/kg) in the prefrontal with imipramine (20 and 30mg/kg)
and harmine (5 and 10mg/kg) in the striatum. In the acute treatment, the complex I increased in the prefrontal with harmine
(15mg/kg) and in the striatum with harmine (10mg/kg); the complex II decreased with imipramine (20 and 30mg/kg) in the
striatum; the complex IV increased with imipramine (30mg/kg) in the striatum. In the chronic treatment, the complex I increased
with harmine (5mg/kg) in the prefrontal; the complex II increased with imipramine (20mg/kg) in the prefrontal; the complex
IV increased with harmine (5mg/kg) in the striatum. Finally, these ﬁndings further support the hypothesis that harmine and
imipramine could be involved in mitochondrial function.
1.Introduction
For more than 30 years, it has been theorized that levels
of monoamines, such as serotonin, norepinephrine, and
dopamine, are generally low in the brain during untreated
major depressive episodes [1]. In fact, the clinically used
antidepressants increase the extracellular concentrations of
monoamines,serotonin,ornorepinephrineeitherbyinhibit-
ing their reuptake from the synapse or by blocking their
degradation by inhibiting monoamine oxidase [2–4].
The β-carboline harmine is present in plants, such as
Peganum harmala and Banisteriopsis caap, which are used
for ritual and medicinal preparations [5]. Also, ingestion
of Ayahuasca, which contains harmine in its composition
improved psychometric measures of panic and hopelessness
in humans [6]. Recently, a growing body of evidence has
indicated that harmine presents antidepressant-like actions
in rodents subjected to an animal model of depression
[7–10]. In addition, studies have demonstrated that harmine
interacts with monoamine oxidase A (MAO-A) [11]a n d2 Depression Research and Treatment
several cell-surface receptors, including serotonin receptor
2A (5-HT2A) [12], which are involved in antidepressant
pharmacotherapy [13].
The creatine/phosphocreatine/CK system is important
for normal to maintain the energy homeostasis [14, 15]
exerting several integrated functions, such as temporary
energy buﬀering, metabolic capacity, energy transfer, and
metabolic control [16]. The brain of adult rats, like other
tissues with high and variable rates of ATP metabolism,
presents high phosphocreatine concentration and creatine
kinase activity [14, 15].
Also important for cellular energy metabolism are the
mitochondria, which are organelles that play a crucial role
in ATP production, a process carried out by the respiratory
chain complexes I, II, III and VI [17]. Besides, studies have
indicated that impairment in the energy metabolism may
be involved in pathophysiology of some neuropsychiatric
disorders, such as bipolar disorder and major depression
[18–20]. In fact, our group recently demonstrated that rats
submitted to the chronic mild stress presented an increased
oxidative stress in submitochondrial particles in the brain
[19].Moreover,wealsodemonstratedareductionincreatine
kinase and citrate synthase activities in brain of rats submit-
ted to the animal model of mania [21, 22]. We recently also
showedthatmitochondrial respiratory chaincomplexesI, II-
III,andIVwereinhibitedafterchronicmildstressincerebral
cortex and cerebellum and acute administration of ketamine
reversed the complexes inhibition [20]. In addition, some
studies have appointed to a role of β-carbolines in energy
metabolism [21] and in oxidative stress [23, 24], which is
involved with mitochondrial function. Also, there is also
a relationship between mitochondria and monoamines. In
fact, we observed decreased levels of serotonin in brain of
mouse with multiple mtDNA deletions [25].
Thus, the main objective of our study was to assess the
eﬀects induced by acute and chronic administration of β-
carboline harmine and tricyclic antidepressant imipramine
ontheenergymetabolisminthebrainofratsbyevaluationof
mitochondrial respiratory chain (complexes I, II, II-III, and
IV) and creatine kinase activities.
2. Results
Acute administration of harmine at the doses of 5, 10, and
15mg/kg and imipramine at the doses of 20 and 30mg/kg
increased creatine kinase activity in the prefrontal cortex
(ANOVA; P<0.05; Figure 1(a)). In the striatum, harmine
at the dose of 5mg/kg and imipramine at the doses of 20
and 30mg/kg increased the creatine kinase activity; however,
harmine at the dose of 15mg/kg decreased creatine kinase
activity in the striatum (ANOVA; P<0.05; Figure 1(a)).
In the chronic treatment with imipramine at the dose of
20mg/kg and harmine at the dose of 5mg/kg occurred an
increase in creatine kinase activity in the prefrontal cortex,
compared to control group (ANOVA; P<0.05; Figure 1(b)).
In the striatum chronic treatment with imipramine at the
doses of 20 and 30mg/kg and harmine at doses of 5 and
10mg/kg increased the creatine kinase activity, compared to
control group (ANOVA; P<0.05; Figure 1(b)).
Figure 2 shows the mitochondrial respiratory chain (I,
II, II-III, and IV) after acute treatment with imipramine
and harmine. The complex I activity increased in prefrontal
cortex after acute treatment of harmine at the dose of
15mg/kg, and in striatum after treatment with harmine at
the dose of 10mg/kg (ANOVA; P<0.05; Figure 2(a));
acute treatment with imipramine did not alter complex I
activity in rat brain. The complex II activity was decreased
after acute treatment with imipramine at the doses of 20
and 30mg/kg in striatum (ANOVA; P<0.05; Figure 2(b));
harmine did not alter complex II activity in both prefrontal
cortex and striatum. The complex II-III activity did not alter
after acute treatment with imipramine or harmine (ANOVA;
P>0.05; Figure 2(c)). The complex IV activity increased
onlyinstriatumafteracutetreatmentwithimipramineatthe
dose of 30mg/kg (ANOVA; P<0.05; Figure 2(d)).
In the chronic treatment with harmine at the dose of
5mg/kg occurred an increase in the complex I activity in
prefrontal cortex (ANOVA; P<0.05; Figure 3(a)), and in
the complex IV activity in striatum (ANOVA; P<0.05;
Figure 3(d)), compared to control group. The complex II
activity increased only in prefrontal cortex with imipramine
at the dose of 20mg/kg (ANOVA; P<0.05; Figure 3(b)).
The complex II-III activity did not alter with chronic
treatment with imipramine or harmine (ANOVA; P>0.05;
Figure 3(c)).
3. Discussion
In the present study we demonstrated that acute and chronic
treatments with harmine or imipramine altered respiratory
chain complexes and creatine kinase activities in the rat
brain. However, we observed that these alterations were de-
pendent on treatment regime, complex, brain area, and drug
concentration.
Studies from our group recently showed that acute treat-
ment with harmine and imipramine decreased immobility
time of rats and increased both climbing and swimming
time of rats; in addition harmine, but not imipramine,
increased BDNF (brain-derived neurotrophic factor) protein
levels in the rat hippocampus [9, 10]. Nevertheless, harmine
reverted the behavioral and physiological parameters caused
to chronic mild stress model [6]. Additionally, Farzin and
Mansouri [7] demonstrated that treatment with harmane,
norharmane, and harmine dose dependently reduced the
immobility time in the mouse.
Damage to the mitochondrial electron transport chain
has been suggested to be an important factor in the patho-
genesis of a range of psychiatric disorders [26–28], including
major depression. In fact, Gardner et al. [29] showed a sig-
niﬁcant decrease in mitochondrial ATP production rates and
mitochondrial enzyme ratios in muscles of major depressive
disorder patients. Madrigal et al. [27] also reported that
complexes I-III and II-III of mitochondrial respiratory
chain were inhibited in rat brain after chronic stress by
immobilization. Our group also recently demonstrated that
mitochondrial respiratory chain was inhibited in brain ofDepression Research and Treatment 3
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Figure1:Eﬀectsoftheacute(a)andchronic(b)administrationofharmine(5,10,and15mg/kg,i.p.)andimipramine(10,20,and30mg/kg,
i.p.) on creatine kinase activity in the prefrontal cortex and striatum of rats. Bars represent means ± SEM of 6 rats. ∗P< 0.05 versus saline
according to ANOVA followed by Tukey post hoc test.
rats after chronic variable stress, suggesting that energy
metabolism impairment may occur in depressive disorders
[20].
Our ﬁndings in the present data showed the eﬀects of the
β-carboline harmine and imipramine on the creatine kinase
activity in the prefrontal cortex and striatum; the brain areas
were used because they are important in psychiatric diseases.
The prefrontal cortex is directly involved in emotion and
cognition and thereby contributes to other major symptoms
of mood disorders [30]. In addition, the striatum is a
dopaminergic area involved to memory [31] and mood
disorders [32].
Our group recently also showed that imipramine in-
creased creatine kinase activity in the striatum, cerebral cor-
tex, cerebellum and prefrontal cortex and did not alter cre-
atine kinase activity in the hippocampus [33]. In another
studywasshowedthatacuteandchronictreatmentswithﬂu-
oxetine decreased the creatine kinase activity in the rat
brain [34], suggesting that the inhibition of creatine kinase
activity by these drugs may be associated to some eﬀects of
ﬂuoxetine.
In this present data we showed that acute and chronic
treatments with harmine or imipramine altered complex I,
II and VI activities in the prefrontal cortex or striatum,
but not complex II-III activities in both treatments. We do
not know how to explain why this eﬀect occurred, but we
suggest that the nonactivation of complex II-III might be
a harmine mechanism of action, possibly harmine leads to
a selective increase of individual mitochondrial respiratory
chain enzyme activities.
The eﬀects of antidepressants in the energy metabolism
have been demonstrated. In fact, prolonged in vivo imi-
pramine treatment sustained stimulation of respiratory
activity, accompanied by increased cytochromes aa3 and
c + c1 content; in addition, the content of cytochrome aa3
increased steadily up to the second week of treatment and
of cytochrome c + c1 steadied state level by the end of the
ﬁrst week [35]. Additionally, an in vitro study from pig brain,
using diﬀerent antidepressants and mood stabilizers, showed
a decrease of I, II, and IV complexes activity [36]. In this
study the authors suggest that these mitochondrial enzymes
may be candidates in searching for new biological markers of
mooddisorders,targetsofnewantidepressants,orpredictors
of response to pharmacotherapy. In addition, antidepressant
treatment inhibited monoamine oxidase A and B in the
mitochondrial fraction of rat brain [37]. Thus, the eﬀects of
harmine on the energy metabolism in the present study may
be related, at least in part, to its action in the monoamine
oxidase or serotonin. In fact, harmine interacts with MAO-
A[ 11] and 5-HT2A [12], and, interestingly, decrease in
serotonin levels was related with mtDNA deletions [25], thus
showing a relationship with monoamines and mitochondria.
The eﬀects of harmine and imipramine in the present
study may also be related to oxidative stress. In fact,
it is well known that the reactive oxygen species cause
damage in the mitochondrial oxidative phosphorylation
system and that reactive oxygen species itself is vulnerable
to the mitochondrial dysfunction [38, 39]. Very recently
we demonstrated that both acute and chronic treatments
with imipramine and harmine reduced lipid and protein
oxidation and increased superoxide dismutase and catalase
in the rat prefrontal cortex and hippocampus, suggesting
positive eﬀects of imipramine antidepressant and harmine
in oxidative stress parameters [24]. Additionally, Zaﬁr et al.
[40] demonstrated that treatment with some antidepressants
recovered the activities of superoxide dismutase, catalase,
glutathione S-transferase, glutathione reductase, glutathione4 Depression Research and Treatment
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Figure 2: Eﬀects of the acute administration of harmine (5, 10 and 15mg/kg, i.p.) and imipramine (10, 20 and 30mg/kg, i.p.) on complex
I (a), II (b), II-III (c), and IV (d) activities in the prefrontal cortex and striatum of rats. Bars represent means ± SEM of 6 rats. ∗P<0.05
versus saline according to ANOVA followed by Tukey post hoc test.
and normalized lipid peroxidation product malondialde-
hyde,andproteincarbonylfollowingstress-inducedrestraint
in rodents.
Moreover,theβ-carbolines,harmalineandharmalol,and
the antioxidants (superoxide dismutase, catalase, ascorbate,
or rutin) prevented the loss of cell viability in PC12
cells treated with methyl-4-phenylpyridinium (MPP+); in
addition, harmaline and harmalol reduced the condensation
and fragmentation of nuclei and inhibited the decrease
in mitochondrial transmembrane potential, cytochrome c
release, activation of caspase-3, formation of reactive oxygen
species, and depletion of glutathione caused by MPP+ in
PC12 cells [23], suggesting a protective eﬀect of β-carboline
on neural cells. In contrast, other study showed that
harmine elicits cytotoxicity via mitochondrial dysfunction
[41], demonstrating that exposure of cell culture hepatocytes
to harmine causes a concentration and time-dependent
decrease in cell viability and losses of intracellular ATP,
adenine nucleotides, glutathione and protein thiols, and an
increase in glutathione disulﬁde and reactive oxygen species.
In this study we suggested that the action mechanism
of imipramine antidepressant and β-carboline harmine may
be, at least in part, involved in the creatine kinase and
mitochondrial respiratory chain activities, but these eﬀects
were dose and treatment relatedin rat brain areas. In conclu-
sion, considering that metabolism impairment is probably
involved in the pathophysiology of depressive disorders, the
modulation of energy metabolism by antidepressants could
be an important mechanism of action of these drugs and
harmine could be studied as a new drug for the treatment
of depression.
4.MaterialsandMethods
4.1. Animals. Male Adult Wistar rats (60 days old) were
obtained from UNESC (Universidade do Extremo Sul
Catarinense, Crici´ uma, SC, Brazil) breeding colony. They
were housed ﬁve per cage with food and water available
ad libitum and were maintained on a 12h light/dark cycle
(lights on at 7:00AM). All experimental procedures involv-
ing animals were performed in accordance with the NIHDepression Research and Treatment 5
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Figure 3:Eﬀectsofthechronicadministrationofharmine(5,10,and15mg/kg,i.p.)andimipramine(10,20,and30mg/kg,i.p.)oncomplex
I (a), II (b), II-III (c), and IV (d) activities in the prefrontal cortex and striatum of rats. Bars represent means ± SEM of 6 rats. ∗P< 0.05
versus saline according to ANOVA followed by Tukey post hoc test.
Guide for the Care and Use of Laboratory Animals and the
Brazilian Society for Neuroscience and Behavior (SBNeC)
recommendations for animal care and with approval by local
Ethics Committee under protocol number 325/2008.
4.2. Drugs and Treatments. Harmine was obtained from
THC-Pharm/STI-Pharm (Frankfurt, Germany) and imi-
pramine, the standard antidepressant, from Novartis Phar-
maceutical Industry (S˜ ao Paulo, Brazil). Diﬀerent groups of
rats (n = 6 each) were administrated intraperitoneally (i.p.)
with saline, (control group) or diﬀerent doses of harmine
(5, 10, and 15mg/kg) or imipramine (10, 20, and 30mg/kg)
one single time (acute treatment) or during 14 days once a
day (chronic treatment) [9, 10]. All treatments were admin-
istered in a volume of 1mL/kg. Two hours after last injection
in both acute and chronic treatments, all rats were killed by
decapitation, and the skulls, prefrontal cortex, and striatum
were removed.
4.3. Tissue and Homogenate Preparation. Prefrontal cortex
and striatum were homogenized (1:10, w/v) in SETH buﬀer,
pH 7.4 (250mM sucrose, 2mM EDTA, 10mM Trizma base,
50IU/mL heparin).
4.4. Creatine Kinase Activity. The homogenates were cen-
trifuged at 800×g for 10min. and the supernatants were
kept at −70◦C until used for creatine kinase activity
determination. The maximal period between homogenate
preparation and enzyme analysis was always less than 5 days.
Protein content was determined by the method described by
Lowry et al. [42], using bovine serum albumin as standard.
Creatine kinase activity was measured in brain homogenates
pretreated with 0.625mM lauryl maltoside. The reaction
mixture consisted of 60mM Tris-HCl, pH 7.5, containing
7mM phosphocreatine, 9mM MgSO4, and approximately
0.4–1.2μg protein in a ﬁnal volume of 100μL. After 15min.
of preincubation at 37◦C, the reaction was started by the
addition of 0.3μmoL of ADP plus 0.08μmoL of reduced
glutathione. The reaction was stopped after 10min. by the
addition of 1μmoL of hydroxymercuribenzoic acid. The
creatine formed was estimated according to the colorimetric
method [43]. The colour was developed by the addition of
100μL2 %α-naphthol and 100μL 0.05% diacetyl in a ﬁnal6 Depression Research and Treatment
volume of 1mL and read spectrophotometrically after 20
minutes at 540nm. Results were expressed as nmoL/m ×mg
protein.
4.5. Respiratory Chain Enzyme Activities. The homogenates
were centrifuged at 800×g for 10min and the supernatants
were kept at –70◦C until used for enzyme activity determina-
tion. The maximal period between homogenate preparation
and enzyme analysis was always less than 5 days. Protein
content was determined by the method described by Lowry
et al. [42] using bovine serum albumin as standard. NADH
dehydrogenase (complex I) was evaluated by the method
described by Cassina and Radi [44] by the rate of NADH-
dependent ferricyanide reduction at 420nm. The activity of
succinate: Cytochrome c oxidoreductase (complexes II-III)
was determined according to the method of Fischer et al.
[45], measured by Cytochrome c reduction from succinate.
The activity of Cytochrome c oxidase (complex IV) was
assayed according to the method described by Rustin et
al. [46], measured by following the decrease in absorbance
due to the oxidation of previously reduced Cytochrome c at
550nm.Theactivitiesofthemitochondrial respiratorychain
c o m p l e x e sw e r ee x p r e s s e da sn m o L /min×mg protein.
4.6. Statistical Analysis. All data are presented as mean ±
SEM. Diﬀerences among experimental groups in the assess-
ment of mitochondrial respiratory chain and creatine kinase
activities were determined by one-way ANOVA, followed by
Tukey post hoc test when ANOVA was signiﬁcant; P<0.05
was considered to be statistically signiﬁcant.
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